Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services, 5625 Fishers Lane, Room 4N03, Bethesda, MD 20892-9415, USA.
Eur J Med Chem. 2012 Apr;50:44-54. doi: 10.1016/j.ejmech.2012.01.025. Epub 2012 Jan 20.
A simple three-step synthesis of 5-(3-hydroxyphenyl)-2-methyl-2-azabicyclo[3.3.1]nonan-4-ol (3a) was achieved using an osmium tetroxide mediated oxidation of the known intermediate 6. A pyrrolidine-ring variant of 3a (3-(7-(hydroxymethyl)-6-methyl-6-azabicyclo[3.2.1]octan-1-yl)phenol (5)) was isolated when other routes were used. The epimeric hydroxy analogue 4a was synthesized by simple inversion of the stereochemistry at C-4. Both N-methyl (3a and 4a) and N-phenethyl (3b and 4b) derivatives were synthesized. The compounds were examined for their opioid receptor affinity and the N-phenethyl analogue 3b was found to have relatively weak affinity for the μ-opioid receptor (K(i) = 74 nM). However, the N-phenethyl analogue of the C-4 epimer, 4b, had about 15 fold higher affinity than 3b and was selective for the μ-opioid receptor (K(i) = 4.6 nM). Compound 4b was a moderately potent μ-opioid antagonist (K(e) = 12 nM), as determined by [(35)S]GTP-γ-S assays. Compounds 3b and 4b were energy minimized at the level of B3LYP/6-31G*, and then overlaid onto the 5-phenylmorphan, the (1R,5R,9S)-(-)-enantiomer of 2b (Fig. 1) with the α or β-OH group at the C-9 position. The spatial orientation of the hydroxyl moiety in 3b, 4b, 2a, and 2b is proposed to be the structural requirement for high μ-opioid receptor binding affinity and their agonist or antagonist activity. The modest change in spatial position of the hydroxyl moiety, and not the N-substituent, induced the change from potent agonist to an antagonist of moderate potency.
实现了 5-(3-羟基苯基)-2-甲基-2-氮杂双环[3.3.1]壬烷-4-醇(3a)的简单三步合成,方法是用过氧化锇介导氧化已知的中间体 6。当使用其他路线时,分离出了 3a 的吡咯烷环变体(3-(7-(羟甲基)-6-甲基-6-氮杂双环[3.2.1]辛烷-1-基)苯酚(5))。通过简单反转 C-4 立体化学,合成了差向异构体羟基类似物 4a。合成了 N-甲基(3a 和 4a)和 N-苯乙基(3b 和 4b)衍生物。研究了这些化合物对阿片受体的亲和力,发现 N-苯乙基类似物 3b 对 μ-阿片受体的亲和力相对较弱(K(i) = 74 nM)。然而,C-4 差向异构体的 N-苯乙基类似物 4b 的亲和力比 3b 高约 15 倍,并且对 μ-阿片受体具有选择性(K(i) = 4.6 nM)。化合物 4b 是一种中等效力的 μ-阿片受体拮抗剂(K(e) = 12 nM),这是通过 [(35)S]GTP-γ-S 测定确定的。在 B3LYP/6-31G* 水平下对 3b 和 4b 进行能量最小化,然后将其叠加到 5-苯并吗啡上,即 2b 的(1R,5R,9S)-(-)-对映体(图 1),C-9 位置的 α 或 β-OH 基团。提出 3b、4b、2a 和 2b 中羟基部分的空间取向是与高 μ-阿片受体结合亲和力及其激动剂或拮抗剂活性相关的结构要求。羟基部分的空间位置的适度变化,而不是 N-取代基,导致从强效激动剂转变为具有中等效力的拮抗剂。